http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104560878-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate | 2015-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104560878-B |
| titleOfInvention | A kind of human intrahepatic cholangiocarcinoma cell line and its application |
| abstract | The present invention relates to a human intrahepatic cholangiocarcinoma cell line and its application. The present invention establishes the human intrahepatic cholangiocarcinoma cell line LICCF, which has clear algebra, no cross-contamination, unique sensitivity to inhibitors of PI3K/mTOR pathway and inhibitors of MEK1/2 pathway, etc. Platinum and FGFR inhibitors are highly resistant, and can be used to construct tumor drug experiments and drug resistance models in vivo and in vitro, in order to reveal the drug resistance mechanism of human intrahepatic cholangiocarcinoma, reverse the emergence of drug resistance, develop new anticancer drugs and screen human liver cancer. Inner cholangiocarcinoma-related biomarkers provide an experimental basis. |
| priorityDate | 2015-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 145.